NCT05564377 2026-03-18
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
11 trialsNCT04585958 2026-03-17
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT03742245 2026-03-16
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
The Methodist Hospital Research Institute
Phase 1 Active not recruiting
NCT02000622 2026-02-13
OlympiAD
AstraZeneca
Phase 3 Completed
NCT06545942 2025-12-23
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
Phase 1 Recruiting
NCT03784014 2025-12-11
MULTISARC
Institut National de la Santé Et de la Recherche Médicale, France
Phase 3 Active not recruiting
NCT05900895 2025-11-20
PHOEBE
Dartmouth-Hitchcock Medical Center
Phase 1 Recruiting
NCT04197713 2025-10-20
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05898399 2025-10-15
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients
Artios Pharma Ltd
Phase 1/2 Active not recruiting
NCT03842228 2025-10-14
COD
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02029001 2025-08-07
MOST plus
Centre Leon Berard
Phase 2 Recruiting